nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP3A5—Beclomethasone—psoriasis	0.0629	0.114	CbGbCtD
Ziprasidone—CYP1A2—Clobetasol propionate—psoriasis	0.0618	0.112	CbGbCtD
Ziprasidone—CYP1A2—Methoxsalen—psoriasis	0.0324	0.0588	CbGbCtD
Ziprasidone—CYP2D6—Hydroxyurea—psoriasis	0.0292	0.053	CbGbCtD
Ziprasidone—CYP3A7—Hydrocortisone—psoriasis	0.0268	0.0486	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0268	0.0486	CbGbCtD
Ziprasidone—CYP3A7—Cyclosporine—psoriasis	0.0253	0.0459	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0253	0.0459	CbGbCtD
Ziprasidone—CYP3A5—Mycophenolate mofetil—psoriasis	0.025	0.0454	CbGbCtD
Ziprasidone—CYP3A4—Calcitriol—psoriasis	0.0219	0.0396	CbGbCtD
Ziprasidone—CYP3A5—Hydrocortisone—psoriasis	0.0201	0.0364	CbGbCtD
Ziprasidone—CYP3A5—Cyclosporine—psoriasis	0.019	0.0344	CbGbCtD
Ziprasidone—CYP2D6—Cholecalciferol—psoriasis	0.0177	0.0321	CbGbCtD
Ziprasidone—CYP3A4—Methoxsalen—psoriasis	0.017	0.0308	CbGbCtD
Ziprasidone—CYP3A7—Dexamethasone—psoriasis	0.0167	0.0302	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0167	0.0302	CbGbCtD
Ziprasidone—CYP3A5—Dexamethasone—psoriasis	0.0125	0.0227	CbGbCtD
Ziprasidone—CYP2D6—Cyclosporine—psoriasis	0.0116	0.0211	CbGbCtD
Ziprasidone—CYP3A4—Cholecalciferol—psoriasis	0.0113	0.0204	CbGbCtD
Ziprasidone—CYP3A4—Mycophenolate mofetil—psoriasis	0.00976	0.0177	CbGbCtD
Ziprasidone—CYP3A4—Triamcinolone—psoriasis	0.00976	0.0177	CbGbCtD
Ziprasidone—CYP3A4—Betamethasone—psoriasis	0.00838	0.0152	CbGbCtD
Ziprasidone—CYP3A4—Prednisolone—psoriasis	0.00826	0.015	CbGbCtD
Ziprasidone—CYP3A4—Hydrocortisone—psoriasis	0.00783	0.0142	CbGbCtD
Ziprasidone—CYP3A4—Prednisone—psoriasis	0.0078	0.0142	CbGbCtD
Ziprasidone—CYP2D6—Dexamethasone—psoriasis	0.00766	0.0139	CbGbCtD
Ziprasidone—CYP3A4—Cyclosporine—psoriasis	0.0074	0.0134	CbGbCtD
Ziprasidone—CYP3A4—Dexamethasone—psoriasis	0.00487	0.00883	CbGbCtD
Ziprasidone—Alopecia—Prednisone—psoriasis	9.04e-05	0.000236	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Cyclosporine—psoriasis	8.99e-05	0.000235	CcSEcCtD
Ziprasidone—Loss of consciousness—Betamethasone—psoriasis	8.99e-05	0.000235	CcSEcCtD
Ziprasidone—Loss of consciousness—Dexamethasone—psoriasis	8.99e-05	0.000235	CcSEcCtD
Ziprasidone—Dizziness—Mycophenolic acid—psoriasis	8.98e-05	0.000235	CcSEcCtD
Ziprasidone—Epistaxis—Methotrexate—psoriasis	8.98e-05	0.000235	CcSEcCtD
Ziprasidone—Paraesthesia—Prednisolone—psoriasis	8.98e-05	0.000235	CcSEcCtD
Ziprasidone—Tachycardia—Triamcinolone—psoriasis	8.98e-05	0.000235	CcSEcCtD
Ziprasidone—Mental disorder—Prednisone—psoriasis	8.96e-05	0.000234	CcSEcCtD
Ziprasidone—Malnutrition—Prednisone—psoriasis	8.91e-05	0.000233	CcSEcCtD
Ziprasidone—Erythema—Prednisone—psoriasis	8.91e-05	0.000233	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Hydrocortisone—psoriasis	8.9e-05	0.000233	CcSEcCtD
Ziprasidone—Hyperhidrosis—Triamcinolone—psoriasis	8.89e-05	0.000233	CcSEcCtD
Ziprasidone—Feeling abnormal—Mycophenolate mofetil—psoriasis	8.84e-05	0.000231	CcSEcCtD
Ziprasidone—Insomnia—Hydrocortisone—psoriasis	8.84e-05	0.000231	CcSEcCtD
Ziprasidone—Hypertension—Dexamethasone—psoriasis	8.83e-05	0.000231	CcSEcCtD
Ziprasidone—Hypertension—Betamethasone—psoriasis	8.83e-05	0.000231	CcSEcCtD
Ziprasidone—Paraesthesia—Hydrocortisone—psoriasis	8.77e-05	0.000229	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	8.77e-05	0.000229	CcSEcCtD
Ziprasidone—Urticaria—Cyclosporine—psoriasis	8.73e-05	0.000228	CcSEcCtD
Ziprasidone—Myalgia—Betamethasone—psoriasis	8.71e-05	0.000228	CcSEcCtD
Ziprasidone—Myalgia—Dexamethasone—psoriasis	8.71e-05	0.000228	CcSEcCtD
Ziprasidone—Abdominal pain—Cyclosporine—psoriasis	8.69e-05	0.000227	CcSEcCtD
Ziprasidone—Body temperature increased—Cyclosporine—psoriasis	8.69e-05	0.000227	CcSEcCtD
Ziprasidone—Anxiety—Dexamethasone—psoriasis	8.68e-05	0.000227	CcSEcCtD
Ziprasidone—Anxiety—Betamethasone—psoriasis	8.68e-05	0.000227	CcSEcCtD
Ziprasidone—Vomiting—Mycophenolic acid—psoriasis	8.64e-05	0.000226	CcSEcCtD
Ziprasidone—Dyspepsia—Hydrocortisone—psoriasis	8.6e-05	0.000225	CcSEcCtD
Ziprasidone—Haemoglobin—Methotrexate—psoriasis	8.59e-05	0.000225	CcSEcCtD
Ziprasidone—Rash—Mycophenolic acid—psoriasis	8.57e-05	0.000224	CcSEcCtD
Ziprasidone—Dermatitis—Mycophenolic acid—psoriasis	8.56e-05	0.000224	CcSEcCtD
Ziprasidone—Haemorrhage—Methotrexate—psoriasis	8.55e-05	0.000224	CcSEcCtD
Ziprasidone—Hepatitis—Methotrexate—psoriasis	8.55e-05	0.000224	CcSEcCtD
Ziprasidone—Urticaria—Mycophenolate mofetil—psoriasis	8.52e-05	0.000223	CcSEcCtD
Ziprasidone—Headache—Mycophenolic acid—psoriasis	8.51e-05	0.000223	CcSEcCtD
Ziprasidone—Decreased appetite—Hydrocortisone—psoriasis	8.49e-05	0.000222	CcSEcCtD
Ziprasidone—Pharyngitis—Methotrexate—psoriasis	8.49e-05	0.000222	CcSEcCtD
Ziprasidone—Body temperature increased—Mycophenolate mofetil—psoriasis	8.48e-05	0.000222	CcSEcCtD
Ziprasidone—Abdominal pain—Mycophenolate mofetil—psoriasis	8.48e-05	0.000222	CcSEcCtD
Ziprasidone—Urinary tract disorder—Methotrexate—psoriasis	8.44e-05	0.000221	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Hydrocortisone—psoriasis	8.43e-05	0.000221	CcSEcCtD
Ziprasidone—Fatigue—Hydrocortisone—psoriasis	8.42e-05	0.00022	CcSEcCtD
Ziprasidone—Vision blurred—Prednisone—psoriasis	8.39e-05	0.000219	CcSEcCtD
Ziprasidone—Urethral disorder—Methotrexate—psoriasis	8.38e-05	0.000219	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Triamcinolone—psoriasis	8.38e-05	0.000219	CcSEcCtD
Ziprasidone—Insomnia—Triamcinolone—psoriasis	8.32e-05	0.000218	CcSEcCtD
Ziprasidone—Infection—Dexamethasone—psoriasis	8.29e-05	0.000217	CcSEcCtD
Ziprasidone—Infection—Betamethasone—psoriasis	8.29e-05	0.000217	CcSEcCtD
Ziprasidone—Paraesthesia—Triamcinolone—psoriasis	8.26e-05	0.000216	CcSEcCtD
Ziprasidone—Feeling abnormal—Prednisolone—psoriasis	8.24e-05	0.000216	CcSEcCtD
Ziprasidone—Visual impairment—Methotrexate—psoriasis	8.24e-05	0.000215	CcSEcCtD
Ziprasidone—Anaemia—Prednisone—psoriasis	8.23e-05	0.000215	CcSEcCtD
Ziprasidone—Shock—Dexamethasone—psoriasis	8.21e-05	0.000215	CcSEcCtD
Ziprasidone—Shock—Betamethasone—psoriasis	8.21e-05	0.000215	CcSEcCtD
Ziprasidone—Dyspnoea—Triamcinolone—psoriasis	8.2e-05	0.000214	CcSEcCtD
Ziprasidone—Nervous system disorder—Dexamethasone—psoriasis	8.18e-05	0.000214	CcSEcCtD
Ziprasidone—Nervous system disorder—Betamethasone—psoriasis	8.18e-05	0.000214	CcSEcCtD
Ziprasidone—Agitation—Prednisone—psoriasis	8.18e-05	0.000214	CcSEcCtD
Ziprasidone—Thrombocytopenia—Dexamethasone—psoriasis	8.17e-05	0.000214	CcSEcCtD
Ziprasidone—Thrombocytopenia—Betamethasone—psoriasis	8.17e-05	0.000214	CcSEcCtD
Ziprasidone—Tachycardia—Betamethasone—psoriasis	8.15e-05	0.000213	CcSEcCtD
Ziprasidone—Tachycardia—Dexamethasone—psoriasis	8.15e-05	0.000213	CcSEcCtD
Ziprasidone—Angioedema—Prednisone—psoriasis	8.14e-05	0.000213	CcSEcCtD
Ziprasidone—Hypersensitivity—Cyclosporine—psoriasis	8.1e-05	0.000212	CcSEcCtD
Ziprasidone—Dyspepsia—Triamcinolone—psoriasis	8.1e-05	0.000212	CcSEcCtD
Ziprasidone—Nausea—Mycophenolic acid—psoriasis	8.07e-05	0.000211	CcSEcCtD
Ziprasidone—Hyperhidrosis—Betamethasone—psoriasis	8.07e-05	0.000211	CcSEcCtD
Ziprasidone—Hyperhidrosis—Dexamethasone—psoriasis	8.07e-05	0.000211	CcSEcCtD
Ziprasidone—Feeling abnormal—Hydrocortisone—psoriasis	8.05e-05	0.00021	CcSEcCtD
Ziprasidone—Vertigo—Prednisone—psoriasis	8e-05	0.000209	CcSEcCtD
Ziprasidone—Eye disorder—Methotrexate—psoriasis	7.99e-05	0.000209	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Hydrocortisone—psoriasis	7.99e-05	0.000209	CcSEcCtD
Ziprasidone—Syncope—Prednisone—psoriasis	7.99e-05	0.000209	CcSEcCtD
Ziprasidone—Tinnitus—Methotrexate—psoriasis	7.97e-05	0.000208	CcSEcCtD
Ziprasidone—Anorexia—Dexamethasone—psoriasis	7.96e-05	0.000208	CcSEcCtD
Ziprasidone—Anorexia—Betamethasone—psoriasis	7.96e-05	0.000208	CcSEcCtD
Ziprasidone—Urticaria—Prednisolone—psoriasis	7.95e-05	0.000208	CcSEcCtD
Ziprasidone—Cardiac disorder—Methotrexate—psoriasis	7.93e-05	0.000207	CcSEcCtD
Ziprasidone—Fatigue—Triamcinolone—psoriasis	7.93e-05	0.000207	CcSEcCtD
Ziprasidone—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.9e-05	0.000207	CcSEcCtD
Ziprasidone—Asthenia—Cyclosporine—psoriasis	7.89e-05	0.000206	CcSEcCtD
Ziprasidone—Loss of consciousness—Prednisone—psoriasis	7.83e-05	0.000205	CcSEcCtD
Ziprasidone—Hypotension—Dexamethasone—psoriasis	7.8e-05	0.000204	CcSEcCtD
Ziprasidone—Hypotension—Betamethasone—psoriasis	7.8e-05	0.000204	CcSEcCtD
Ziprasidone—Urticaria—Hydrocortisone—psoriasis	7.76e-05	0.000203	CcSEcCtD
Ziprasidone—Angiopathy—Methotrexate—psoriasis	7.76e-05	0.000203	CcSEcCtD
Ziprasidone—Immune system disorder—Methotrexate—psoriasis	7.72e-05	0.000202	CcSEcCtD
Ziprasidone—Abdominal pain—Hydrocortisone—psoriasis	7.72e-05	0.000202	CcSEcCtD
Ziprasidone—Body temperature increased—Hydrocortisone—psoriasis	7.72e-05	0.000202	CcSEcCtD
Ziprasidone—Mediastinal disorder—Methotrexate—psoriasis	7.71e-05	0.000201	CcSEcCtD
Ziprasidone—Asthenia—Mycophenolate mofetil—psoriasis	7.69e-05	0.000201	CcSEcCtD
Ziprasidone—Hypertension—Prednisone—psoriasis	7.69e-05	0.000201	CcSEcCtD
Ziprasidone—Chills—Methotrexate—psoriasis	7.67e-05	0.000201	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Dexamethasone—psoriasis	7.6e-05	0.000199	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Betamethasone—psoriasis	7.6e-05	0.000199	CcSEcCtD
Ziprasidone—Arthralgia—Prednisone—psoriasis	7.58e-05	0.000198	CcSEcCtD
Ziprasidone—Myalgia—Prednisone—psoriasis	7.58e-05	0.000198	CcSEcCtD
Ziprasidone—Feeling abnormal—Triamcinolone—psoriasis	7.58e-05	0.000198	CcSEcCtD
Ziprasidone—Anxiety—Prednisone—psoriasis	7.56e-05	0.000198	CcSEcCtD
Ziprasidone—Alopecia—Methotrexate—psoriasis	7.55e-05	0.000198	CcSEcCtD
Ziprasidone—Insomnia—Dexamethasone—psoriasis	7.55e-05	0.000197	CcSEcCtD
Ziprasidone—Insomnia—Betamethasone—psoriasis	7.55e-05	0.000197	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	7.53e-05	0.000197	CcSEcCtD
Ziprasidone—Diarrhoea—Cyclosporine—psoriasis	7.52e-05	0.000197	CcSEcCtD
Ziprasidone—Paraesthesia—Betamethasone—psoriasis	7.49e-05	0.000196	CcSEcCtD
Ziprasidone—Paraesthesia—Dexamethasone—psoriasis	7.49e-05	0.000196	CcSEcCtD
Ziprasidone—Mental disorder—Methotrexate—psoriasis	7.49e-05	0.000196	CcSEcCtD
Ziprasidone—Malnutrition—Methotrexate—psoriasis	7.44e-05	0.000195	CcSEcCtD
Ziprasidone—Erythema—Methotrexate—psoriasis	7.44e-05	0.000195	CcSEcCtD
Ziprasidone—Hypersensitivity—Prednisolone—psoriasis	7.37e-05	0.000193	CcSEcCtD
Ziprasidone—Dyspepsia—Dexamethasone—psoriasis	7.35e-05	0.000192	CcSEcCtD
Ziprasidone—Dyspepsia—Betamethasone—psoriasis	7.35e-05	0.000192	CcSEcCtD
Ziprasidone—Diarrhoea—Mycophenolate mofetil—psoriasis	7.34e-05	0.000192	CcSEcCtD
Ziprasidone—Urticaria—Triamcinolone—psoriasis	7.31e-05	0.000191	CcSEcCtD
Ziprasidone—Body temperature increased—Triamcinolone—psoriasis	7.27e-05	0.00019	CcSEcCtD
Ziprasidone—Dizziness—Cyclosporine—psoriasis	7.27e-05	0.00019	CcSEcCtD
Ziprasidone—Decreased appetite—Dexamethasone—psoriasis	7.25e-05	0.00019	CcSEcCtD
Ziprasidone—Decreased appetite—Betamethasone—psoriasis	7.25e-05	0.00019	CcSEcCtD
Ziprasidone—Infection—Prednisone—psoriasis	7.22e-05	0.000189	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Betamethasone—psoriasis	7.21e-05	0.000188	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Dexamethasone—psoriasis	7.21e-05	0.000188	CcSEcCtD
Ziprasidone—Back pain—Methotrexate—psoriasis	7.2e-05	0.000188	CcSEcCtD
Ziprasidone—Hypersensitivity—Hydrocortisone—psoriasis	7.2e-05	0.000188	CcSEcCtD
Ziprasidone—Fatigue—Dexamethasone—psoriasis	7.2e-05	0.000188	CcSEcCtD
Ziprasidone—Fatigue—Betamethasone—psoriasis	7.2e-05	0.000188	CcSEcCtD
Ziprasidone—Shock—Prednisone—psoriasis	7.15e-05	0.000187	CcSEcCtD
Ziprasidone—Nervous system disorder—Prednisone—psoriasis	7.13e-05	0.000186	CcSEcCtD
Ziprasidone—Tachycardia—Prednisone—psoriasis	7.09e-05	0.000185	CcSEcCtD
Ziprasidone—Dizziness—Mycophenolate mofetil—psoriasis	7.09e-05	0.000185	CcSEcCtD
Ziprasidone—Skin disorder—Prednisone—psoriasis	7.06e-05	0.000185	CcSEcCtD
Ziprasidone—Hyperhidrosis—Prednisone—psoriasis	7.03e-05	0.000184	CcSEcCtD
Ziprasidone—Vision blurred—Methotrexate—psoriasis	7.01e-05	0.000183	CcSEcCtD
Ziprasidone—Asthenia—Hydrocortisone—psoriasis	7.01e-05	0.000183	CcSEcCtD
Ziprasidone—Vomiting—Cyclosporine—psoriasis	6.99e-05	0.000183	CcSEcCtD
Ziprasidone—Rash—Cyclosporine—psoriasis	6.93e-05	0.000181	CcSEcCtD
Ziprasidone—Anorexia—Prednisone—psoriasis	6.93e-05	0.000181	CcSEcCtD
Ziprasidone—Dermatitis—Cyclosporine—psoriasis	6.92e-05	0.000181	CcSEcCtD
Ziprasidone—Headache—Cyclosporine—psoriasis	6.89e-05	0.00018	CcSEcCtD
Ziprasidone—Anaemia—Methotrexate—psoriasis	6.88e-05	0.00018	CcSEcCtD
Ziprasidone—Feeling abnormal—Betamethasone—psoriasis	6.88e-05	0.00018	CcSEcCtD
Ziprasidone—Feeling abnormal—Dexamethasone—psoriasis	6.88e-05	0.00018	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Dexamethasone—psoriasis	6.82e-05	0.000178	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Betamethasone—psoriasis	6.82e-05	0.000178	CcSEcCtD
Ziprasidone—Vomiting—Mycophenolate mofetil—psoriasis	6.82e-05	0.000178	CcSEcCtD
Ziprasidone—Hypersensitivity—Triamcinolone—psoriasis	6.78e-05	0.000177	CcSEcCtD
Ziprasidone—Rash—Mycophenolate mofetil—psoriasis	6.76e-05	0.000177	CcSEcCtD
Ziprasidone—Dermatitis—Mycophenolate mofetil—psoriasis	6.75e-05	0.000177	CcSEcCtD
Ziprasidone—Headache—Mycophenolate mofetil—psoriasis	6.72e-05	0.000176	CcSEcCtD
Ziprasidone—Vertigo—Methotrexate—psoriasis	6.69e-05	0.000175	CcSEcCtD
Ziprasidone—Diarrhoea—Hydrocortisone—psoriasis	6.68e-05	0.000175	CcSEcCtD
Ziprasidone—Leukopenia—Methotrexate—psoriasis	6.66e-05	0.000174	CcSEcCtD
Ziprasidone—Urticaria—Dexamethasone—psoriasis	6.63e-05	0.000173	CcSEcCtD
Ziprasidone—Urticaria—Betamethasone—psoriasis	6.63e-05	0.000173	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Prednisone—psoriasis	6.62e-05	0.000173	CcSEcCtD
Ziprasidone—Dizziness—Prednisolone—psoriasis	6.61e-05	0.000173	CcSEcCtD
Ziprasidone—Asthenia—Triamcinolone—psoriasis	6.6e-05	0.000173	CcSEcCtD
Ziprasidone—Abdominal pain—Betamethasone—psoriasis	6.6e-05	0.000173	CcSEcCtD
Ziprasidone—Abdominal pain—Dexamethasone—psoriasis	6.6e-05	0.000173	CcSEcCtD
Ziprasidone—Body temperature increased—Betamethasone—psoriasis	6.6e-05	0.000173	CcSEcCtD
Ziprasidone—Body temperature increased—Dexamethasone—psoriasis	6.6e-05	0.000173	CcSEcCtD
Ziprasidone—Insomnia—Prednisone—psoriasis	6.57e-05	0.000172	CcSEcCtD
Ziprasidone—Nausea—Cyclosporine—psoriasis	6.53e-05	0.000171	CcSEcCtD
Ziprasidone—Paraesthesia—Prednisone—psoriasis	6.53e-05	0.000171	CcSEcCtD
Ziprasidone—Cough—Methotrexate—psoriasis	6.49e-05	0.00017	CcSEcCtD
Ziprasidone—Dizziness—Hydrocortisone—psoriasis	6.46e-05	0.000169	CcSEcCtD
Ziprasidone—Dyspepsia—Prednisone—psoriasis	6.4e-05	0.000167	CcSEcCtD
Ziprasidone—Nausea—Mycophenolate mofetil—psoriasis	6.37e-05	0.000167	CcSEcCtD
Ziprasidone—Arthralgia—Methotrexate—psoriasis	6.34e-05	0.000166	CcSEcCtD
Ziprasidone—Myalgia—Methotrexate—psoriasis	6.34e-05	0.000166	CcSEcCtD
Ziprasidone—Chest pain—Methotrexate—psoriasis	6.34e-05	0.000166	CcSEcCtD
Ziprasidone—Decreased appetite—Prednisone—psoriasis	6.32e-05	0.000165	CcSEcCtD
Ziprasidone—Rash—Prednisolone—psoriasis	6.31e-05	0.000165	CcSEcCtD
Ziprasidone—Dermatitis—Prednisolone—psoriasis	6.3e-05	0.000165	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	6.29e-05	0.000165	CcSEcCtD
Ziprasidone—Fatigue—Prednisone—psoriasis	6.27e-05	0.000164	CcSEcCtD
Ziprasidone—Headache—Prednisolone—psoriasis	6.27e-05	0.000164	CcSEcCtD
Ziprasidone—Constipation—Prednisone—psoriasis	6.22e-05	0.000163	CcSEcCtD
Ziprasidone—Vomiting—Hydrocortisone—psoriasis	6.21e-05	0.000162	CcSEcCtD
Ziprasidone—Rash—Hydrocortisone—psoriasis	6.16e-05	0.000161	CcSEcCtD
Ziprasidone—Dermatitis—Hydrocortisone—psoriasis	6.15e-05	0.000161	CcSEcCtD
Ziprasidone—Confusional state—Methotrexate—psoriasis	6.12e-05	0.00016	CcSEcCtD
Ziprasidone—Headache—Hydrocortisone—psoriasis	6.12e-05	0.00016	CcSEcCtD
Ziprasidone—Dizziness—Triamcinolone—psoriasis	6.08e-05	0.000159	CcSEcCtD
Ziprasidone—Infection—Methotrexate—psoriasis	6.03e-05	0.000158	CcSEcCtD
Ziprasidone—Feeling abnormal—Prednisone—psoriasis	5.99e-05	0.000157	CcSEcCtD
Ziprasidone—Asthenia—Betamethasone—psoriasis	5.99e-05	0.000157	CcSEcCtD
Ziprasidone—Asthenia—Dexamethasone—psoriasis	5.99e-05	0.000157	CcSEcCtD
Ziprasidone—Nervous system disorder—Methotrexate—psoriasis	5.96e-05	0.000156	CcSEcCtD
Ziprasidone—Thrombocytopenia—Methotrexate—psoriasis	5.95e-05	0.000156	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Prednisone—psoriasis	5.94e-05	0.000155	CcSEcCtD
Ziprasidone—Nausea—Prednisolone—psoriasis	5.94e-05	0.000155	CcSEcCtD
Ziprasidone—Skin disorder—Methotrexate—psoriasis	5.9e-05	0.000154	CcSEcCtD
Ziprasidone—Hyperhidrosis—Methotrexate—psoriasis	5.87e-05	0.000154	CcSEcCtD
Ziprasidone—Vomiting—Triamcinolone—psoriasis	5.85e-05	0.000153	CcSEcCtD
Ziprasidone—Nausea—Hydrocortisone—psoriasis	5.8e-05	0.000152	CcSEcCtD
Ziprasidone—Rash—Triamcinolone—psoriasis	5.8e-05	0.000152	CcSEcCtD
Ziprasidone—Dermatitis—Triamcinolone—psoriasis	5.79e-05	0.000152	CcSEcCtD
Ziprasidone—Anorexia—Methotrexate—psoriasis	5.79e-05	0.000151	CcSEcCtD
Ziprasidone—Urticaria—Prednisone—psoriasis	5.77e-05	0.000151	CcSEcCtD
Ziprasidone—Headache—Triamcinolone—psoriasis	5.76e-05	0.000151	CcSEcCtD
Ziprasidone—Abdominal pain—Prednisone—psoriasis	5.75e-05	0.00015	CcSEcCtD
Ziprasidone—Body temperature increased—Prednisone—psoriasis	5.75e-05	0.00015	CcSEcCtD
Ziprasidone—Diarrhoea—Dexamethasone—psoriasis	5.71e-05	0.000149	CcSEcCtD
Ziprasidone—Diarrhoea—Betamethasone—psoriasis	5.71e-05	0.000149	CcSEcCtD
Ziprasidone—Hypotension—Methotrexate—psoriasis	5.68e-05	0.000148	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Methotrexate—psoriasis	5.53e-05	0.000145	CcSEcCtD
Ziprasidone—Dizziness—Dexamethasone—psoriasis	5.52e-05	0.000144	CcSEcCtD
Ziprasidone—Dizziness—Betamethasone—psoriasis	5.52e-05	0.000144	CcSEcCtD
Ziprasidone—Insomnia—Methotrexate—psoriasis	5.49e-05	0.000144	CcSEcCtD
Ziprasidone—Nausea—Triamcinolone—psoriasis	5.46e-05	0.000143	CcSEcCtD
Ziprasidone—Paraesthesia—Methotrexate—psoriasis	5.45e-05	0.000143	CcSEcCtD
Ziprasidone—Dyspnoea—Methotrexate—psoriasis	5.42e-05	0.000142	CcSEcCtD
Ziprasidone—Somnolence—Methotrexate—psoriasis	5.4e-05	0.000141	CcSEcCtD
Ziprasidone—Hypersensitivity—Prednisone—psoriasis	5.35e-05	0.00014	CcSEcCtD
Ziprasidone—Dyspepsia—Methotrexate—psoriasis	5.35e-05	0.00014	CcSEcCtD
Ziprasidone—Vomiting—Betamethasone—psoriasis	5.31e-05	0.000139	CcSEcCtD
Ziprasidone—Vomiting—Dexamethasone—psoriasis	5.31e-05	0.000139	CcSEcCtD
Ziprasidone—Decreased appetite—Methotrexate—psoriasis	5.28e-05	0.000138	CcSEcCtD
Ziprasidone—Rash—Dexamethasone—psoriasis	5.26e-05	0.000138	CcSEcCtD
Ziprasidone—Rash—Betamethasone—psoriasis	5.26e-05	0.000138	CcSEcCtD
Ziprasidone—Dermatitis—Betamethasone—psoriasis	5.26e-05	0.000137	CcSEcCtD
Ziprasidone—Dermatitis—Dexamethasone—psoriasis	5.26e-05	0.000137	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Methotrexate—psoriasis	5.24e-05	0.000137	CcSEcCtD
Ziprasidone—Fatigue—Methotrexate—psoriasis	5.24e-05	0.000137	CcSEcCtD
Ziprasidone—Headache—Dexamethasone—psoriasis	5.23e-05	0.000137	CcSEcCtD
Ziprasidone—Headache—Betamethasone—psoriasis	5.23e-05	0.000137	CcSEcCtD
Ziprasidone—Asthenia—Prednisone—psoriasis	5.21e-05	0.000136	CcSEcCtD
Ziprasidone—Feeling abnormal—Methotrexate—psoriasis	5.01e-05	0.000131	CcSEcCtD
Ziprasidone—Diarrhoea—Prednisone—psoriasis	4.97e-05	0.00013	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Methotrexate—psoriasis	4.97e-05	0.00013	CcSEcCtD
Ziprasidone—Nausea—Betamethasone—psoriasis	4.96e-05	0.00013	CcSEcCtD
Ziprasidone—Nausea—Dexamethasone—psoriasis	4.96e-05	0.00013	CcSEcCtD
Ziprasidone—Urticaria—Methotrexate—psoriasis	4.83e-05	0.000126	CcSEcCtD
Ziprasidone—Dizziness—Prednisone—psoriasis	4.81e-05	0.000126	CcSEcCtD
Ziprasidone—Body temperature increased—Methotrexate—psoriasis	4.8e-05	0.000126	CcSEcCtD
Ziprasidone—Abdominal pain—Methotrexate—psoriasis	4.8e-05	0.000126	CcSEcCtD
Ziprasidone—Vomiting—Prednisone—psoriasis	4.62e-05	0.000121	CcSEcCtD
Ziprasidone—Rash—Prednisone—psoriasis	4.58e-05	0.00012	CcSEcCtD
Ziprasidone—Dermatitis—Prednisone—psoriasis	4.58e-05	0.00012	CcSEcCtD
Ziprasidone—Headache—Prednisone—psoriasis	4.55e-05	0.000119	CcSEcCtD
Ziprasidone—Hypersensitivity—Methotrexate—psoriasis	4.48e-05	0.000117	CcSEcCtD
Ziprasidone—Asthenia—Methotrexate—psoriasis	4.36e-05	0.000114	CcSEcCtD
Ziprasidone—Nausea—Prednisone—psoriasis	4.32e-05	0.000113	CcSEcCtD
Ziprasidone—Diarrhoea—Methotrexate—psoriasis	4.16e-05	0.000109	CcSEcCtD
Ziprasidone—Dizziness—Methotrexate—psoriasis	4.02e-05	0.000105	CcSEcCtD
Ziprasidone—Vomiting—Methotrexate—psoriasis	3.86e-05	0.000101	CcSEcCtD
Ziprasidone—Rash—Methotrexate—psoriasis	3.83e-05	0.0001	CcSEcCtD
Ziprasidone—Dermatitis—Methotrexate—psoriasis	3.83e-05	0.0001	CcSEcCtD
Ziprasidone—Headache—Methotrexate—psoriasis	3.81e-05	9.95e-05	CcSEcCtD
Ziprasidone—Nausea—Methotrexate—psoriasis	3.61e-05	9.43e-05	CcSEcCtD
Ziprasidone—CHRM1—Signaling by GPCR—CXCL8—psoriasis	9.09e-06	0.000138	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—NFKBIA—psoriasis	9.07e-06	0.000137	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—CXCL8—psoriasis	9.06e-06	0.000137	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—CXCL8—psoriasis	8.97e-06	0.000136	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—LEP—psoriasis	8.95e-06	0.000136	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—APOE—psoriasis	8.95e-06	0.000136	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—CXCL8—psoriasis	8.94e-06	0.000136	CbGpPWpGaD
Ziprasidone—ADRA2A—Hemostasis—TP53—psoriasis	8.89e-06	0.000135	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—VEGFA—psoriasis	8.88e-06	0.000135	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—APOE—psoriasis	8.84e-06	0.000134	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—STAT3—psoriasis	8.79e-06	0.000133	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—NFKBIA—psoriasis	8.76e-06	0.000133	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TYK2—psoriasis	8.76e-06	0.000133	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—NFKBIA—psoriasis	8.71e-06	0.000132	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—NFKBIA—psoriasis	8.48e-06	0.000128	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—CXCL8—psoriasis	8.44e-06	0.000128	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—CXCL8—psoriasis	8.43e-06	0.000128	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PPARG—psoriasis	8.39e-06	0.000127	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—CXCL8—psoriasis	8.37e-06	0.000127	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TYK2—psoriasis	8.34e-06	0.000126	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—NFKBIA—psoriasis	8.34e-06	0.000126	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	8.31e-06	0.000126	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—LEP—psoriasis	8.25e-06	0.000125	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—APOE—psoriasis	8.25e-06	0.000125	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TYK2—psoriasis	8.23e-06	0.000125	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—CXCL8—psoriasis	8.2e-06	0.000124	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—LEP—psoriasis	8.12e-06	0.000123	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—APOE—psoriasis	8.12e-06	0.000123	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—LEP—psoriasis	8.1e-06	0.000123	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—APOE—psoriasis	8.1e-06	0.000123	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—APOE—psoriasis	8.1e-06	0.000123	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—APOE—psoriasis	8.08e-06	0.000122	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—LEP—psoriasis	8.08e-06	0.000122	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—CXCL8—psoriasis	8.07e-06	0.000122	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—LEP—psoriasis	8.05e-06	0.000122	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—APOE—psoriasis	8.05e-06	0.000122	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—IL6—psoriasis	8.02e-06	0.000122	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—IL6—psoriasis	8.02e-06	0.000121	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—APOE—psoriasis	7.97e-06	0.000121	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—LEP—psoriasis	7.97e-06	0.000121	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—IL6—psoriasis	7.96e-06	0.000121	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—CXCL8—psoriasis	7.96e-06	0.000121	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—LEP—psoriasis	7.95e-06	0.00012	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—APOE—psoriasis	7.95e-06	0.00012	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CARM1—psoriasis	7.88e-06	0.000119	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—JUN—psoriasis	7.85e-06	0.000119	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—JUN—psoriasis	7.84e-06	0.000119	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—IL6—psoriasis	7.8e-06	0.000118	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—JUN—psoriasis	7.79e-06	0.000118	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PPARG—psoriasis	7.7e-06	0.000117	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—NFKBIA—psoriasis	7.69e-06	0.000117	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—IL6—psoriasis	7.67e-06	0.000116	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—CXCL8—psoriasis	7.62e-06	0.000115	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—JUN—psoriasis	7.62e-06	0.000115	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—TP53—psoriasis	7.58e-06	0.000115	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—IL6—psoriasis	7.57e-06	0.000115	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—NFKBIA—psoriasis	7.57e-06	0.000115	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—NFKB1—psoriasis	7.55e-06	0.000114	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—NFKBIA—psoriasis	7.55e-06	0.000114	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—NFKB1—psoriasis	7.54e-06	0.000114	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—NFKBIA—psoriasis	7.53e-06	0.000114	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—NFKBIA—psoriasis	7.5e-06	0.000114	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—JUN—psoriasis	7.5e-06	0.000114	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—NFKB1—psoriasis	7.49e-06	0.000114	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TYK2—psoriasis	7.43e-06	0.000113	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—NFKBIA—psoriasis	7.43e-06	0.000113	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—CAT—psoriasis	7.41e-06	0.000112	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—NFKBIA—psoriasis	7.41e-06	0.000112	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—JUN—psoriasis	7.4e-06	0.000112	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—LEP—psoriasis	7.39e-06	0.000112	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—APOE—psoriasis	7.39e-06	0.000112	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—NFKB1—psoriasis	7.34e-06	0.000111	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—CXCL8—psoriasis	7.26e-06	0.00011	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—IL6—psoriasis	7.25e-06	0.00011	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—NFKB1—psoriasis	7.22e-06	0.000109	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TYK2—psoriasis	7.17e-06	0.000109	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—CXCL8—psoriasis	7.17e-06	0.000109	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TYK2—psoriasis	7.14e-06	0.000108	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—NFKB1—psoriasis	7.12e-06	0.000108	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—JUN—psoriasis	7.09e-06	0.000107	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PPARG—psoriasis	7.05e-06	0.000107	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TYK2—psoriasis	6.94e-06	0.000105	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—IL6—psoriasis	6.94e-06	0.000105	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—IL6—psoriasis	6.91e-06	0.000105	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	6.88e-06	0.000104	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—VEGFA—psoriasis	6.85e-06	0.000104	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—VEGFA—psoriasis	6.85e-06	0.000104	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TYK2—psoriasis	6.83e-06	0.000104	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—NFKB1—psoriasis	6.82e-06	0.000103	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—IL6—psoriasis	6.82e-06	0.000103	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—VEGFA—psoriasis	6.8e-06	0.000103	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—STAT3—psoriasis	6.79e-06	0.000103	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—STAT3—psoriasis	6.78e-06	0.000103	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—JUN—psoriasis	6.75e-06	0.000102	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—STAT3—psoriasis	6.73e-06	0.000102	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—TP53—psoriasis	6.71e-06	0.000102	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—JUN—psoriasis	6.66e-06	0.000101	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—VEGFA—psoriasis	6.66e-06	0.000101	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—STAT3—psoriasis	6.59e-06	9.99e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—VEGFA—psoriasis	6.55e-06	9.93e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—NFKB1—psoriasis	6.5e-06	9.85e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—STAT3—psoriasis	6.49e-06	9.83e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CXCL8—psoriasis	6.47e-06	9.8e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—VEGFA—psoriasis	6.47e-06	9.79e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—NFKB1—psoriasis	6.41e-06	9.72e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—STAT3—psoriasis	6.4e-06	9.7e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TYK2—psoriasis	6.3e-06	9.54e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CAT—psoriasis	6.28e-06	9.51e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CXCL8—psoriasis	6.25e-06	9.46e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CXCL8—psoriasis	6.21e-06	9.41e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TYK2—psoriasis	6.2e-06	9.39e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—VEGFA—psoriasis	6.19e-06	9.38e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TYK2—psoriasis	6.18e-06	9.37e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TYK2—psoriasis	6.16e-06	9.34e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—IL6—psoriasis	6.15e-06	9.32e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TYK2—psoriasis	6.15e-06	9.31e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—IL6—psoriasis	6.14e-06	9.3e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—STAT3—psoriasis	6.13e-06	9.29e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TYK2—psoriasis	6.09e-06	9.22e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TYK2—psoriasis	6.07e-06	9.19e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CXCL8—psoriasis	6.04e-06	9.16e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—JUN—psoriasis	6.02e-06	9.11e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CXCL8—psoriasis	5.95e-06	9.01e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—IL6—psoriasis	5.94e-06	9e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—IL6—psoriasis	5.91e-06	8.95e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—VEGFA—psoriasis	5.9e-06	8.94e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—STAT3—psoriasis	5.84e-06	8.85e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—VEGFA—psoriasis	5.82e-06	8.82e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—JUN—psoriasis	5.81e-06	8.8e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—NFKB1—psoriasis	5.79e-06	8.77e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—JUN—psoriasis	5.78e-06	8.75e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—STAT3—psoriasis	5.76e-06	8.73e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—APOE—psoriasis	5.76e-06	8.72e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—IL6—psoriasis	5.75e-06	8.71e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—IL6—psoriasis	5.66e-06	8.57e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TYK2—psoriasis	5.64e-06	8.54e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—JUN—psoriasis	5.62e-06	8.51e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—NFKB1—psoriasis	5.59e-06	8.47e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—NFKB1—psoriasis	5.56e-06	8.42e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—JUN—psoriasis	5.53e-06	8.38e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CXCL8—psoriasis	5.48e-06	8.31e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—NFKB1—psoriasis	5.41e-06	8.19e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CXCL8—psoriasis	5.4e-06	8.18e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CXCL8—psoriasis	5.38e-06	8.16e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CXCL8—psoriasis	5.37e-06	8.13e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CXCL8—psoriasis	5.35e-06	8.11e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—NFKB1—psoriasis	5.32e-06	8.06e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CXCL8—psoriasis	5.3e-06	8.03e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CXCL8—psoriasis	5.28e-06	8e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—VEGFA—psoriasis	5.26e-06	7.96e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—IL6—psoriasis	5.22e-06	7.9e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—STAT3—psoriasis	5.2e-06	7.88e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TP53—psoriasis	5.18e-06	7.85e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TP53—psoriasis	5.17e-06	7.84e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TP53—psoriasis	5.14e-06	7.79e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—IL6—psoriasis	5.13e-06	7.77e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—IL6—psoriasis	5.12e-06	7.76e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—IL6—psoriasis	5.1e-06	7.73e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—JUN—psoriasis	5.1e-06	7.72e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—IL6—psoriasis	5.09e-06	7.71e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—VEGFA—psoriasis	5.07e-06	7.69e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—VEGFA—psoriasis	5.05e-06	7.65e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—IL6—psoriasis	5.04e-06	7.63e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TP53—psoriasis	5.03e-06	7.62e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—IL6—psoriasis	5.02e-06	7.61e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—STAT3—psoriasis	5.02e-06	7.61e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—JUN—psoriasis	5.02e-06	7.6e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PPARG—psoriasis	5.01e-06	7.6e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—JUN—psoriasis	5.01e-06	7.58e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—STAT3—psoriasis	5e-06	7.57e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—JUN—psoriasis	4.99e-06	7.56e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—JUN—psoriasis	4.97e-06	7.54e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—psoriasis	4.95e-06	7.5e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—JUN—psoriasis	4.93e-06	7.46e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—JUN—psoriasis	4.91e-06	7.44e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CXCL8—psoriasis	4.91e-06	7.44e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—VEGFA—psoriasis	4.91e-06	7.44e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—NFKB1—psoriasis	4.91e-06	7.44e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—psoriasis	4.89e-06	7.4e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—APOE—psoriasis	4.88e-06	7.39e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—STAT3—psoriasis	4.86e-06	7.36e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CAT—psoriasis	4.84e-06	7.34e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—VEGFA—psoriasis	4.83e-06	7.32e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—NFKB1—psoriasis	4.83e-06	7.32e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—NFKB1—psoriasis	4.82e-06	7.3e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—NFKB1—psoriasis	4.8e-06	7.28e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—NFKB1—psoriasis	4.79e-06	7.25e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—STAT3—psoriasis	4.78e-06	7.25e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—NFKB1—psoriasis	4.74e-06	7.18e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IL6—psoriasis	4.74e-06	7.18e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IL6—psoriasis	4.73e-06	7.17e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—NFKB1—psoriasis	4.73e-06	7.16e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IL6—psoriasis	4.7e-06	7.13e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—psoriasis	4.68e-06	7.09e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—IL6—psoriasis	4.67e-06	7.07e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IL6—psoriasis	4.61e-06	6.98e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—JUN—psoriasis	4.56e-06	6.91e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IL6—psoriasis	4.53e-06	6.87e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IL6—psoriasis	4.47e-06	6.77e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—psoriasis	4.46e-06	6.75e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—VEGFA—psoriasis	4.45e-06	6.75e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—STAT3—psoriasis	4.41e-06	6.68e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—psoriasis	4.4e-06	6.66e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—NFKB1—psoriasis	4.39e-06	6.66e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—VEGFA—psoriasis	4.38e-06	6.64e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—VEGFA—psoriasis	4.37e-06	6.63e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—VEGFA—psoriasis	4.36e-06	6.6e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—VEGFA—psoriasis	4.35e-06	6.58e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—STAT3—psoriasis	4.34e-06	6.57e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—STAT3—psoriasis	4.33e-06	6.56e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—STAT3—psoriasis	4.32e-06	6.54e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—VEGFA—psoriasis	4.3e-06	6.52e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—STAT3—psoriasis	4.3e-06	6.52e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—VEGFA—psoriasis	4.29e-06	6.5e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL6—psoriasis	4.28e-06	6.49e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—STAT3—psoriasis	4.26e-06	6.46e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—STAT3—psoriasis	4.25e-06	6.44e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PPARG—psoriasis	4.25e-06	6.44e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL6—psoriasis	4.08e-06	6.18e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL6—psoriasis	4.03e-06	6.1e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—VEGFA—psoriasis	3.99e-06	6.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—psoriasis	3.97e-06	6.02e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—STAT3—psoriasis	3.95e-06	5.98e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—psoriasis	3.83e-06	5.81e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—psoriasis	3.81e-06	5.78e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—APOE—psoriasis	3.76e-06	5.7e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—psoriasis	3.71e-06	5.62e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—psoriasis	3.65e-06	5.53e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL6—psoriasis	3.63e-06	5.51e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL6—psoriasis	3.51e-06	5.32e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL6—psoriasis	3.49e-06	5.29e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL6—psoriasis	3.4e-06	5.14e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—psoriasis	3.37e-06	5.1e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL6—psoriasis	3.34e-06	5.06e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—psoriasis	3.31e-06	5.02e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—psoriasis	3.3e-06	5.01e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—psoriasis	3.29e-06	4.99e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—psoriasis	3.28e-06	4.97e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PPARG—psoriasis	3.28e-06	4.97e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—psoriasis	3.25e-06	4.93e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—psoriasis	3.24e-06	4.91e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL6—psoriasis	3.08e-06	4.67e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL6—psoriasis	3.03e-06	4.59e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL6—psoriasis	3.02e-06	4.58e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL6—psoriasis	3.02e-06	4.57e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—psoriasis	3.01e-06	4.56e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL6—psoriasis	3.01e-06	4.55e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL6—psoriasis	2.98e-06	4.51e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL6—psoriasis	2.97e-06	4.5e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL6—psoriasis	2.76e-06	4.18e-05	CbGpPWpGaD
